Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.

This article discusses the potential effects of exogenous testosterone, highlighting that its impact on prostate cancer progression, cardiovascular health, and behavior remains uncertain and needs further investigation.

This review found strong evidence supporting Finasteride's effectiveness in reducing symptoms and improving quality of life in patients with larger prostate volumes, earning it a grade A recommendation for clinical use.

Finasteride reduces prostate size and symptoms with few side effects.

This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.

This study reports on biofeedback treatment for dysfunctional voiding in three adult cases, providing insights into this condition when diagnosed beyond childhood.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

This study concluded that daily treatment with 1 mg finasteride did not affect spermatogenesis or semen production in young men and had small, reversible effects on prostate volume and serum PSA.

This paper discusses risk factors and prevention strategies for acute urinary retention secondary to benign prostatic hyperplasia, emphasizing the role of PSA levels and the benefits of medications like finasteride and alpha-blockers, but reports no new clinical results.

This review summarizes a meta-analysis suggesting that finasteride is most effective for improving symptoms and urinary flow in men with large prostates experiencing benign prostatic hyperplasia.

This study found that transdermal DHT treatment increased penile length in boys with 5α-reductase type 2 deficiency, but post-pubertal growth was limited and carried potential prostate complications.

Dutasteride reduces DHT more effectively than finasteride.

This study found that finasteride reduced prostate cancer incidence by 30%, with no significant difference in Gleason scores compared to placebo after re-evaluation of pathology and extended follow-up.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

This editorial comment reports no new clinical findings, instead discussing a study on the effectiveness of combination therapy with doxazosin and finasteride in patients with benign prostatic hyperplasia.

This abstract reviews testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production and reports no new research findings.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

This study found that nonobese women with idiopathic hirsutism had significantly lower nitrite/nitrate concentrations and higher fibrinogen levels compared to controls, but similar levels to women with PCOS.

This research concludes that finasteride significantly reduces dihydrotestosterone levels and prostate size in men with BPH and may improve urinary symptoms, with greater baseline prostate size predicting more pronounced benefits compared to placebo.

Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.

This study reports that in young male patients with finasteride-associated infertility, semen parameters appear reversible after discontinuing the medication.

This study found that in men, elevated androgen levels can occur at any age, with older men potentially exhibiting increased total testosterone due to higher levels of SHBG, and younger men showing various clinical manifestations like acne and alopecia.

This review discusses the sexual side effects of medical and surgical treatments for benign prostatic hyperplasia, such as erectile dysfunction and changes in ejaculation, but presents no new clinical findings.

In this study, a 12-week treatment with Angelicae Gigantis Radix and Glycyrrhizae Radix complex was well tolerated and showed therapeutic effects on moderate lower urinary tract symptoms in men.

Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

This study found that treating dogs with benign prostatic hyperplasia using osaterone acetate reduced prostatic volume and increased diffusion times of an ultrasound contrast agent, suggesting effective treatment and potential for CEUS monitoring.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.